Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: Sanofi
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
News Wire ~ 3rd Party Press Release
-
2022/09/19
Infants and young children finally get relief from eczema’s terrible itch
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
News Wire ~ 3rd Party Press Release
-
2022/07/15
Majority of patients achieved histological disease remission in 16 weeks.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...
News Wire ~ 3rd Party Press Release
-
2022/04/12
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
Sanofi Presses Court Battle with Mylan in Appeal of EpiPen Antitrust...
Dave Bloom
-
2021/06/07
With billions at stake, Sanofi ups the ante with Mylan in their EpiPen suit.
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
News Wire ~ 3rd Party Press Release
-
2020/05/28
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit
Dave Bloom
-
2019/08/13
Sordid details of anticompetitive behavior alleged in court filing.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
News Wire ~ 3rd Party Press Release
-
2019/03/12
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
News Wire ~ 3rd Party Press Release
-
2018/10/15
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Dave Bloom
-
2018/09/27
Study scheduled to commence next week.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
News Wire ~ 3rd Party Press Release
-
2018/05/17
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
1
2
3
Page 1 of 3